New virotherapy trial involving Reolysin® opens for myeloma patients

The Canadian biotechnology company, Oncolytics Biotech. Inc., has recently opened a Phase 1b trial of its proprietary drug Reolysin in combination with Velcade® and dexamethasone for relapsed and/or refractory myeloma patients. Reolysin is a variant of the reovirus (Respiratory Enteric Orphan Virus) that is known to infect and selectively destroy cancer cell, particularly those with…

Details

Ninlaro® (ixazomib) approved by FDA as a treatment for myeloma

Takeda, the Japanese pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has approved the use of ixazomib as a treatment for relapsed myeloma patients who have received at least one prior line of treatment. Ixazomib is the first, and currently only oral proteasome inhibitor, to be licensed and is indicated for…

Details